2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-145276
    SARS-CoV-2-IN-10
    		Inhibitor
    SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
    SARS-CoV-2-IN-10
  • HY-B0260S2
    Methylprednisolone-d4
    		Inhibitor
    Methylprednisolone-d4 is deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.
    Methylprednisolone-d<sub>4</sub>
  • HY-156979
    RBT-9
    		Inhibitor
    RBT-9 prevents progression to severe COVID-19 and organ failure. RBT-9 also has antiviral effects, as demonstrated in several enveloped viruses, including influenza, HCV, dengue, and yellow fever.
    RBT-9
  • HY-152224
    SPR41
    		Inhibitor
    SPR41 is a potent SARS-CoV-2 main protease inhibitor with Ki values of 0.184, 0.252, 14.4 µM for SARS-CoV-2 Mpro, hCatL, hCatB, respectively. SPR41 shows antiviral and cytotoxicity.
    SPR41
  • HY-105721
    Aranotin
    		Inhibitor
    Aranotin strongly binds to Nsp15 viral protein. Aranotin can be used as promising SARS-CoV-2 replication strong inhibitor. Aranotin has the potential for COVID-19 research.
    Aranotin
  • HY-154990
    RdRP-IN-7
    		Inhibitor
    RdRP-IN-7 is a RNA-dependent RNA polymerase (RdRp) inhibitor that shows the inhibition of SARS-CoV-2 infection with an IC50 of 8.2 μM, an IC90 of 14.1 μM and an CC90 of 79.1 μM. RdRP-IN-7 can be used for antiviral research.
    RdRP-IN-7
  • HY-145973
    3'OMe-m7GpppAmpG
    		Inhibitor
    3’OMe-m7GpppAmpG (m7(3'OMeG)(5')ppp(5')(2'OMeA)pG) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3’OMe-m7GpppAmpG effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3’OMe-m7GpppAmpG is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research.
    3'OMe-m7GpppAmpG
  • HY-155015
    SARS-CoV-2-IN-45
    		Inhibitor
    SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC50 of 0.5 μM, and has no evident cytotoxic effect.
    SARS-CoV-2-IN-45
  • HY-146987
    FWM-3
    		Inhibitor
    FWM-3 is a potent SARS-CoV-2 NSP13 helicase inhibitor.
    FWM-3
  • HY-124439
    Setomimycin
    		Inhibitor
    Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC50 value of 12.02 µM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity.
    Setomimycin
  • HY-163706
    SARS-CoV-2-IN-88
    		Inhibitor
    SARS-CoV-2-IN-88 (compound 3a) is a potent SARS-CoV-2 inhibitor with inhibitory value of 96.00%.
    SARS-CoV-2-IN-88
  • HY-N10604
    Dihydromaniwamycin E
    		Inhibitor
    Dihydromaniwamycin E is a heat-shock metabolite with antiviral activity against influenza and SARS-CoV-2 viruses.
    Dihydromaniwamycin E
  • HY-168152
    SARS-CoV-2 3CLpro-IN-26
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is an allosteric inhibitor for SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. SARS-CoV-2 3CLpro-IN-26 exhibits good cell permeability and is able to effectively cross the cell membrane, after co-incubation with Vero-E6 cells.
    SARS-CoV-2 3CLpro-IN-26
  • HY-147804
    SARS-CoV-2 3CLpro-IN-3
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities.
    SARS-CoV-2 3CLpro-IN-3
  • HY-181661
    YL1004
    		Inhibitor
    YL1004 is a potent, selective and orally active noncovalent inhibitor of SARS-CoV-2 papain-like protease (PLpro). YL1004 shows an IC50 of 17.5 nM and a Ki of 2.3 nM against PLpro, with an in vitro anti-SARS-CoV-2 EC50 of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PLpro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection).
    YL1004
  • HY-90001S2
    Ritonavir-d8
    		Inhibitor
    Ritonavir-d8 is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.
    Ritonavir-d<sub>8</sub>
  • HY-152220
    SPR39
    		Inhibitor
    SPR39 is a potent SARS-CoV-2 main protease inhibitor with Ki values of 0.252, 3.38, 7.88 µM for SARS-CoV-2 Mpro, hCatL, hCatB, respectively. SPR39 shows antiviral and cytotoxicity.
    SPR39
  • HY-152009
    SARS-CoV-2 3CLpro-IN-7
    		Inhibitor
    SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 1.4 µM.
    SARS-CoV-2 3CLpro-IN-7
  • HY-156325
    SARS-CoV-2-IN-62
    		Inhibitor
    SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC50 values of 2.97 μM and 3.82 μM, respectively.
    SARS-CoV-2-IN-62
  • HY-133832
    Elopiprazole
    		Inhibitor
    Elopiprazole can be used in study of neurological disease and SARS-CoV-2.
    Elopiprazole
Cat. No. Product Name / Synonyms Species Source